Marvin Rios, MD
Endocrinology, Diabetes & Metabolism · Minneapolis, MNNPI 1992190680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,838 and has fallen 74.7% since, to $464 in 2025.
Across 266 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$526
- Dexcom, Inc.$492
- Abbott$467
- Corcept Therapeutics$431
- AstraZeneca$414
- Lilly USA, LLC$379
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,15299%
- Education$120%
- Entertainment$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $526 |
| Dexcom, Inc. | 23 | $492 |
| Abbott | 28 | $467 |
| Corcept Therapeutics | 17 | $431 |
| AstraZeneca | 14 | $414 |
| Lilly USA, LLC | 24 | $379 |
| BETA Bionics, Inc. | 19 | $309 |
| Medtronic(2 entities) | 16 | $286 |
| Tandem Diabetes Care, Inc. | 8 | $283 |
| Amgen | 9 | $281 |
| Bayer | 11 | $225 |
| Xeris Pharmaceuticals, Inc. | 12 | $197 |
| Antares Pharma, Inc. | 9 | $139 |
| Insulet Corporation | 1 | $103 |
| Amarin Pharma, Inc. | 7 | $101 |
| Boehringer Ingelheim | 6 | $96 |
| Merck | 6 | $82 |
| Novartis | 3 | $46 |
| Radius Health, Inc. | 2 | $40 |
| Recordati_rare_diseases_inc. | 3 | $39 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Halozyme Inc | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $32 |
| Lifescan, Inc. | 2 | $32 |
| Optos, Inc. | 1 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- FREESTYLE LIBRE 3$125
- DEXCOM G6 TRANSMITTER$123
- Wegovy$122
- MINIMED 780G$117
- EVENITY$116
- Korlym$115
- t:slim X2 Insulin Pump with Control-IQ$111
- Omnipod$103
How this compares
$5,196 in reported general payments places this provider in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 164 | $233,401 |
| OzempicSemaglutide | 144 | $228,693 |
| TrulicityDulaglutide | 87 | $138,238 |
| JardianceEmpagliflozin | 53 | $70,988 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $65,056 |
| FarxigaDapagliflozin Propanediol | 36 | $49,177 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $37,096 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $32,046 |
| RybelsusSemaglutide | 20 | $31,005 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $30,222 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $23,487 |
| HumalogInsulin Lispro | 21 | $12,254 |
| KerendiaFinerenone | 14 | $11,503 |
| Novolog FlexpenInsulin Aspart | 23 | $11,356 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $10,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $379 | $383,893272 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $526 | $266,087179 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $96 | $118,51392 claims |
| AstraZenecaFarxiga | $414 | $49,17736 claims |
| BayerKerendia | $225 | $11,50314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Minneapolis
- Maria CaramoriMinneapolis$147K
- Crispin SemakulaMinneapolis$34K
- Ameer KhowajaMinneapolis$28K
- Takako ArakiMinneapolis$12K
- Elizabeth SeaquistMinneapolis$4K
- Lisa FishMinneapolis$1K
- Sreekant AvulaMinneapolis$1K
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.